Gerard C.M. Linssen

TL;DR: Administration of the NHE-1 inhibitor eniporide, before reperfusion therapy in patients with acute ST elevation MI, did not limit infarct size or improve clinical outcome, but there was a significant reduction of the incidence of heart failure in patients reperfused late (>4 h).

TL;DR: The therapeutic effects of sacubitril/valsartan, compared with a renin-angiotensin-aldosterone–system inhibitor alone, vary by LVEF with treatment benefits, particularly for heart failure hospitalization, that appear to extend to patients with heart failure and mildly reduced ejection fraction.

TL;DR: Resolute ZES were noninferior to Xience V EES in treating "real-world" patients with a vast majority of complex lesions and "off-label" indications for drug-eluting stents, which were implanted with liberal use of post-dilation.

TL;DR: This large-scale, investigator-initiated, multicentre, assessor and patient blinded, three-arm, randomised, BIO-RESORT non-inferiority trial investigated in allcomers the safety and efficacy of three stents eluting either everolimus, sirolimus, or zotarlimus, of which the biodegradable polymer everolitus-eluting stent was never before assessed.

TL;DR: Ease of stent delivery was shown by very low numbers of patients requiring treatment other than their assigned study treatment, and non-inferior to the everolimus-eluting stent, and 12-month follow-up results were available for 1810 patients.